NYSE: DOCHealthpeak Properties Inc Stock
$21.38-0.11 (-0.51%)
Updated Dec 6, 2024
DOC Price
$21.38
Fair Value Price
N/A
Market Cap
$14.95B
52 Week Low
$16.02
52 Week High
$23.26
P/E
45.49x
P/B
1.75x
P/S
6.26x
PEG
0.75x
Dividend Yield
1.4%
Revenue
$2.56B
Earnings
$309.54M
Gross Margin
60%
Operating Margin
22.64%
Profit Margin
12.1%
Debt to Equity
1.26
Operating Cash Flow
$1B
Beta
1.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DOC Overview
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns and develops high-quality real estate in the three private-pay healthcare asset classes of Life Science, Medical Office and Senior Housing, designed to provide stability through the inevitable industry cycles. At Healthpeak, we pair our deep understanding of the healthcare real estate market with a strong vision for long-term growth.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DOC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
B
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Facility REIT
Industry Rating
D
DOC
Ranked#12 of 16
Ranked#12 of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.83 | B | |
| $37.73 | B | |
| $39.25 | C |
Be the first to know about important DOC news, forecast changes, insider trades & much more!
DOC News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DOC scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DOC ($21.38) is trading above its intrinsic value of $12.76, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DOC is poor value based on its earnings relative to its share price (45.49x), compared to the US market average (29.86x)
P/E vs Market Valuation
DOC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more DOC due diligence checks available for Premium users.
Valuation
DOC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
45.49x
Industry
-12.81x
Market
29.86x
DOC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DOC is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
DOC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.75x
Industry
2.13x
DOC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DOC price to earnings growth (PEG)
For valuing profitable companies with growth potential
DOC is good value based... subscribe to Premium to read more.
PEG Value Valuation
DOC's financial health
Profit margin
Revenue
$700.4M
Net Income
$85.9M
Profit Margin
12.2%
DOC's Earnings (EBIT) of $578.77M... subscribe to Premium to read more.
Interest Coverage Financials
DOC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$20.0B
Liabilities
$10.7B
Debt to equity
1.26
DOC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DOC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$318.2M
Investing
$30.2M
Financing
-$265.7M
DOC's operating cash flow ($1.02B)... subscribe to Premium to read more.
Debt Coverage Financials
DOC vs Healthcare Facility REIT Stocks
Healthpeak Properties Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.